| Policy (N = 17) | Practice (N = 14) | T-test; p-value | ES Cohen | ||||
---|---|---|---|---|---|---|---|---|
 | Rank | M | SD | Rank | M | SD |  | d |
Staffing resources | 1 | 3.21 | 0.33 | 5 | 3.11 | 0.44 | t = 0.76, p = 0.45 | 0.27 |
Costs of EBP | 2 | 3.13 | 0.53 | 4 | 3.14 | 0.72 | t = 0.02, p = 0.99 | 0.01 |
Funding | 3 | 3.11 | 0.35 | 2 | 3.24 | 0.81 | t = 0.60, p = 0.55 | 0.21 |
Research and Outcomes Supporting EBP | 4 | 3.09 | 0.44 | 6 | 3.09 | 0.60 | t = 0.00, p = 0.99 | 0.00 |
Staff Development and Support | 5 | 3.06 | 0.28 | 1 | 3.28 | 0.49 | t = 1.56, p = 0.13 | 0.55 |
Political Dynamics | 6 | 2.92 | 0.60 | 12 | 2.88 | 0.78 | t = 0.16, p = 0.87 | 0.06 |
Beneficial features (of EBP) | 7 | 2.82 | 0.47 | 8 | 3.07 | 0.75 | t = 1.12, p = 0.27 | 0.39 |
Consumer Values and Marketing | 8 | 2.72 | 0.47 | 9 | 3.05 | 0.69 | t = 1.54, p = 0.14 | 0.54 |
Consumer Concerns | 9 | 2.71 | 0.37 | 10 | 3.01 | 0.66 | t = 1.58, p = 0.13 | 0.55 |
Clinical Perceptions | 10 | 2.70 | 0.63 | 6 | 3.09 | 0.45 | t = 2.63, p = 0.01 | 0.69 |
EBP Limitations | 11 | 2.67 | 0.65 | 14 | 2.74 | 0.69 | t = 0.30, p = 0.77 | 0.10 |
System Readiness and Compatibility | 11 | 2.67 | 0.57 | 11 | 2.96 | 0.71 | t = 1.21, p = 0.24 | 0.43 |
Agency Compatibility | 13 | 2.52 | 0.47 | 13 | 2.87 | 0.58 | t = 1.90, p = 0.07 | 0.67 |
Impact on Clinical Practice | 14 | 2.48 | 0.50 | 3 | 3.21 | 0.59 | t = 3.72, p < 0.01 | 1.33 |